Multiple myeloma is a malignant proliferative disease of plasma cells caused by genetics, ionizing radiation, chemicals, viral infection, and antigenic stimulation. Common clinical manifestations are bone pain, anemia, renal impairment, increased blood calcium and infection, etc. Multiple myeloma is divided into two cases, symptomatic myeloma and asymptomatic myeloma, with different diagnostic criteria: i. Symptomatic myeloma: need to meet both Article 1, 2, and any of Article 3; 1. Plasma cells: bone marrow monoclonal plasma cell ratio ≥ 10% and/or tissue biopsy proving the presence of plasmacytoma. 2, M protein: the presence of monoclonal M protein in serum and/or urine; 3, related manifestations caused by myeloma: (1) manifestations of target organ damage (CRAB): [C] corrected serum calcium >2.75 mmol/L; [R] manifestations of renal impairment with creatinine clearance <40 ml/min or serum creatinine >177 μmol/L; [A] hemoglobin below the lower limit of normal of 20 g/ L or <100g/L as a manifestation of anemia; [B] one or more osteolytic lesions demonstrated by imaging such as X-ray, CT or PET-CT; (2) no manifestation of target organ damage: but one or more of the following indicators are abnormal, including the proportion of bone marrow monoclonal plasma cells ≥ 60%, the ratio of involved or non-involved serum free light chain ≥ 100, and the presence of >1 5-mm or more on MRI focal bone destruction. II. Asymptomatic myeloma: Article 3, and Article 1 and/or 2 need to be satisfied. 1. serum monoclonal M protein ≥ 30 g/L or 24-hour urinary light chain ≥ 0.5 g; 2. bone marrow monoclonal plasma cell ratio 10%-60%; 3. no damage to associated organs and tissues, i.e. no end-organ damage manifested by SLiM-CRAB, etc. In case of prolonged and unexplained severe bone pain, anemia, abnormal kidney function, or recurrent infections, it is recommended that the above-mentioned relevant examinations be performed promptly under the guidance of a doctor to confirm the presence of multiple myeloma.